Our products use targeted radiation to better inform treatment decisions and deliver personalised therapy in areas of significant unmet medical need.
Telix is a global, commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals.
Telix’s extensive pipeline for urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning is underpinned by a strong global supply, manufacturing and distribution network.
Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent and has more than 18 clinical trials underway worldwide.
Latest News
See all
Craig Stankiewicz is a husband, father and business professional from Chicago, Illinois. In August 2021, Craig was diagnosed with glioblastoma (GBM) and almost five years on he continues to face the disease, using his experience to help others with the same…
Read more
